Inhibrx Biosciences, Inc. Share Price & Technical Analysis
INBX · $91.25 (-4.17%)
Healthcare / Biotechnology
$91.25
-4.17%
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-base…
Price chart
Seasonality
Jun has 1 positive and 2 negative years (last 3 years shown)
-12% return in Jun, -4% avg return in past 3 year Jun month.
42% return in 2026, 142% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | -2% | -7% | 88% | -19% | -12% | – | – | – | – | – | – | 42% |
| 25 | -11% | 0% | 7% | -12% | 10% | 6% | 55% | 31% | 21% | 144% | 5% | -7% | 249% |
| 24 | – | – | – | – | 38% | -14% | 4% | 0% | 8% | 3% | -6% | 2% | 35% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.33B
P/E ratio
—
52W high
$155.3
52W low
$12.80
Volume
2,64,376
Beta
3.89
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Inhibrx Biosciences, Inc. share price today?
- Inhibrx Biosciences, Inc. (INBX) last traded around $91.25 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INBX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INBX. Download the app for real-time alerts.
- How can I analyze Inhibrx Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.